最新!iPSCs建立多发性内分泌瘤疾病模型获进展

2022-08-14 中国科学报、科学网、科学新闻杂志 中国科学报、科学网、科学新闻杂志

中国科学院广州生物医药与健康研究院研究员李尹雄课题组等利用患者来源的诱导性多能干细胞(iPSCs)建立多发性内分泌瘤疾病模型取得进展。

2022861636413321

MEN1病人来源的iPSCs建立MEN1疾病模型及其相关机制示意图。研究团队 供图

中国科学院广州生物医药与健康研究院研究员李尹雄课题组等利用患者来源的诱导性多能干细胞(iPSCs)建立多发性内分泌瘤疾病模型取得进展。相关研究近日发表于Cells。博士研究生程子淇为该论文第一作者,李尹雄为通讯作者。该项研究的合作单位为暨南大学附属广州复大肿瘤医院。

该研究通过收集多发性内分泌瘤I型(MEN1)病人尿液细胞重编程为iPSCs,结合体外胰岛β样细胞分化和免疫缺陷小鼠移植实验,成功地再现了MEN1高胰岛素分泌这一的关键表型及其背后的机制,建立了MEN1的疾病模型,并发现GLP-1R通路是治疗由胰岛素瘤导致的高胰岛素血症的潜在靶点

MEN1 是一种的罕见遗传病,MEN1基因突变导致多种内分泌器官和腺体(包括甲状腺、甲状旁腺、肾上腺和胰腺等)的肿瘤发生,其中胰腺内分泌肿瘤(PNETs)的发病率最高,其高胰岛素血症导致的低血糖昏迷是致命的。由于MEN1突变位点众多,其编码蛋白的功能复杂,相同基因型的MEN1小鼠模型,出现不同的表型,其基因型和表型的关系存在不确定性;而且,人类的胰腺和啮齿类的胰腺存在结构和生理上的较大差异;因此,基于患者iPSCs的基因型和表观遗传记忆构建MEN1疾病模型,有望克服单纯的小鼠基因操作存在的基因型-表型不统一的缺陷。

在本项研究工作中,研究人员通过收集一个MEN1家庭中母子两位患者的尿液,建立了重编程细胞株,在MEN1-iPSC分化的胰岛β样细胞阶段,重现高胰岛素分泌的临床表型。该表型的基础是MEN1细胞从胰祖细胞阶段开始,表现出强大的增殖能力,产生大量的胰岛β样细胞,导致高胰岛素分泌。

探究其病理机制,发现受MEN1负调控的胰高血糖素样肽-1(GLP-1)的分泌上调,通过结合GLP-1R,激活PI3K/AKT信号传导,改变了调控β细胞增殖两个关键转录因子FOXO1和CREB的磷酸化,导致FOXO1和CREB的失衡,引起 MEN1来源胰岛素阳性细胞的高增殖和高胰岛素分泌。GLP-1R或PI3K的抑制剂可以逆转这种表型,阐明GLP-1R是导致MEN1胰腺内分泌瘤的高胰岛素血症的病理关键和潜在的治疗靶点。

进一步免疫缺陷小鼠移植实验发现,不同干细胞阶段的MEN1细胞不能成瘤,只有移植MEN1胰岛β样细胞才可以形成肿瘤,并表达与患者原位肿瘤一致的PNETs标志物。提示iPSCs不仅保留了患者的基因型,同时还维持了其时空的表观记忆能力。基于患者iPSCs构建的MEN1 疾病模型,克服了基因型和表型不确定的缺陷,为深入探究分子病理和药物研发提供了理想的MEN1疾病模型。

相关研究工作得到了国家重点研发计划基金、国家自然科学基金、广东省基础与应用基础研究基金等项目的支持。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1736521, encodeId=19011e36521e5, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Tue Nov 29 13:30:05 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693374, encodeId=713d16933e49a, content=<a href='/topic/show?id=155ae068838' target=_blank style='color:#2F92EE;'>#疾病模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70688, encryptionId=155ae068838, topicName=疾病模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d72329409973, createdName=guguangxiang, createdTime=Fri Oct 28 12:30:05 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682742, encodeId=e6a21682e421c, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun May 07 17:30:05 CST 2023, time=2023-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890403, encodeId=6a02189040377, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jul 22 22:30:05 CST 2023, time=2023-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377803, encodeId=d18213e78033f, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404305, encodeId=c539140430514, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448790, encodeId=8f9d1448e9096, content=<a href='/topic/show?id=c6dd1000849' target=_blank style='color:#2F92EE;'>#iPSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10008, encryptionId=c6dd1000849, topicName=iPSCs)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/27ddabe24d5c43739f1308f83d97be8c/4e3d31f92c9f4025bcf1d53b255ca4e5.jpg, createdBy=ffb85431490, createdName=caoliehu, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538833, encodeId=e8a9153883354, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37d013060412, createdName=neurosurgeon, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=)]
    2022-11-29 贵阳
  2. [GetPortalCommentsPageByObjectIdResponse(id=1736521, encodeId=19011e36521e5, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Tue Nov 29 13:30:05 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693374, encodeId=713d16933e49a, content=<a href='/topic/show?id=155ae068838' target=_blank style='color:#2F92EE;'>#疾病模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70688, encryptionId=155ae068838, topicName=疾病模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d72329409973, createdName=guguangxiang, createdTime=Fri Oct 28 12:30:05 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682742, encodeId=e6a21682e421c, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun May 07 17:30:05 CST 2023, time=2023-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890403, encodeId=6a02189040377, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jul 22 22:30:05 CST 2023, time=2023-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377803, encodeId=d18213e78033f, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404305, encodeId=c539140430514, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448790, encodeId=8f9d1448e9096, content=<a href='/topic/show?id=c6dd1000849' target=_blank style='color:#2F92EE;'>#iPSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10008, encryptionId=c6dd1000849, topicName=iPSCs)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/27ddabe24d5c43739f1308f83d97be8c/4e3d31f92c9f4025bcf1d53b255ca4e5.jpg, createdBy=ffb85431490, createdName=caoliehu, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538833, encodeId=e8a9153883354, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37d013060412, createdName=neurosurgeon, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1736521, encodeId=19011e36521e5, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Tue Nov 29 13:30:05 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693374, encodeId=713d16933e49a, content=<a href='/topic/show?id=155ae068838' target=_blank style='color:#2F92EE;'>#疾病模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70688, encryptionId=155ae068838, topicName=疾病模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d72329409973, createdName=guguangxiang, createdTime=Fri Oct 28 12:30:05 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682742, encodeId=e6a21682e421c, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun May 07 17:30:05 CST 2023, time=2023-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890403, encodeId=6a02189040377, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jul 22 22:30:05 CST 2023, time=2023-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377803, encodeId=d18213e78033f, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404305, encodeId=c539140430514, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448790, encodeId=8f9d1448e9096, content=<a href='/topic/show?id=c6dd1000849' target=_blank style='color:#2F92EE;'>#iPSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10008, encryptionId=c6dd1000849, topicName=iPSCs)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/27ddabe24d5c43739f1308f83d97be8c/4e3d31f92c9f4025bcf1d53b255ca4e5.jpg, createdBy=ffb85431490, createdName=caoliehu, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538833, encodeId=e8a9153883354, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37d013060412, createdName=neurosurgeon, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=)]
    2023-05-07 gwc392
  4. [GetPortalCommentsPageByObjectIdResponse(id=1736521, encodeId=19011e36521e5, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Tue Nov 29 13:30:05 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693374, encodeId=713d16933e49a, content=<a href='/topic/show?id=155ae068838' target=_blank style='color:#2F92EE;'>#疾病模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70688, encryptionId=155ae068838, topicName=疾病模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d72329409973, createdName=guguangxiang, createdTime=Fri Oct 28 12:30:05 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682742, encodeId=e6a21682e421c, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun May 07 17:30:05 CST 2023, time=2023-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890403, encodeId=6a02189040377, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jul 22 22:30:05 CST 2023, time=2023-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377803, encodeId=d18213e78033f, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404305, encodeId=c539140430514, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448790, encodeId=8f9d1448e9096, content=<a href='/topic/show?id=c6dd1000849' target=_blank style='color:#2F92EE;'>#iPSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10008, encryptionId=c6dd1000849, topicName=iPSCs)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/27ddabe24d5c43739f1308f83d97be8c/4e3d31f92c9f4025bcf1d53b255ca4e5.jpg, createdBy=ffb85431490, createdName=caoliehu, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538833, encodeId=e8a9153883354, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37d013060412, createdName=neurosurgeon, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=)]
    2023-07-22 jml2009
  5. [GetPortalCommentsPageByObjectIdResponse(id=1736521, encodeId=19011e36521e5, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Tue Nov 29 13:30:05 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693374, encodeId=713d16933e49a, content=<a href='/topic/show?id=155ae068838' target=_blank style='color:#2F92EE;'>#疾病模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70688, encryptionId=155ae068838, topicName=疾病模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d72329409973, createdName=guguangxiang, createdTime=Fri Oct 28 12:30:05 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682742, encodeId=e6a21682e421c, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun May 07 17:30:05 CST 2023, time=2023-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890403, encodeId=6a02189040377, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jul 22 22:30:05 CST 2023, time=2023-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377803, encodeId=d18213e78033f, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404305, encodeId=c539140430514, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448790, encodeId=8f9d1448e9096, content=<a href='/topic/show?id=c6dd1000849' target=_blank style='color:#2F92EE;'>#iPSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10008, encryptionId=c6dd1000849, topicName=iPSCs)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/27ddabe24d5c43739f1308f83d97be8c/4e3d31f92c9f4025bcf1d53b255ca4e5.jpg, createdBy=ffb85431490, createdName=caoliehu, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538833, encodeId=e8a9153883354, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37d013060412, createdName=neurosurgeon, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=)]
    2022-08-15 chengjn
  6. [GetPortalCommentsPageByObjectIdResponse(id=1736521, encodeId=19011e36521e5, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Tue Nov 29 13:30:05 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693374, encodeId=713d16933e49a, content=<a href='/topic/show?id=155ae068838' target=_blank style='color:#2F92EE;'>#疾病模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70688, encryptionId=155ae068838, topicName=疾病模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d72329409973, createdName=guguangxiang, createdTime=Fri Oct 28 12:30:05 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682742, encodeId=e6a21682e421c, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun May 07 17:30:05 CST 2023, time=2023-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890403, encodeId=6a02189040377, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jul 22 22:30:05 CST 2023, time=2023-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377803, encodeId=d18213e78033f, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404305, encodeId=c539140430514, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448790, encodeId=8f9d1448e9096, content=<a href='/topic/show?id=c6dd1000849' target=_blank style='color:#2F92EE;'>#iPSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10008, encryptionId=c6dd1000849, topicName=iPSCs)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/27ddabe24d5c43739f1308f83d97be8c/4e3d31f92c9f4025bcf1d53b255ca4e5.jpg, createdBy=ffb85431490, createdName=caoliehu, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538833, encodeId=e8a9153883354, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37d013060412, createdName=neurosurgeon, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=)]
    2022-08-15 gjsgj
  7. [GetPortalCommentsPageByObjectIdResponse(id=1736521, encodeId=19011e36521e5, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Tue Nov 29 13:30:05 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693374, encodeId=713d16933e49a, content=<a href='/topic/show?id=155ae068838' target=_blank style='color:#2F92EE;'>#疾病模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70688, encryptionId=155ae068838, topicName=疾病模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d72329409973, createdName=guguangxiang, createdTime=Fri Oct 28 12:30:05 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682742, encodeId=e6a21682e421c, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun May 07 17:30:05 CST 2023, time=2023-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890403, encodeId=6a02189040377, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jul 22 22:30:05 CST 2023, time=2023-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377803, encodeId=d18213e78033f, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404305, encodeId=c539140430514, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448790, encodeId=8f9d1448e9096, content=<a href='/topic/show?id=c6dd1000849' target=_blank style='color:#2F92EE;'>#iPSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10008, encryptionId=c6dd1000849, topicName=iPSCs)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/27ddabe24d5c43739f1308f83d97be8c/4e3d31f92c9f4025bcf1d53b255ca4e5.jpg, createdBy=ffb85431490, createdName=caoliehu, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538833, encodeId=e8a9153883354, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37d013060412, createdName=neurosurgeon, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=)]
    2022-08-15 caoliehu
  8. [GetPortalCommentsPageByObjectIdResponse(id=1736521, encodeId=19011e36521e5, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Tue Nov 29 13:30:05 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693374, encodeId=713d16933e49a, content=<a href='/topic/show?id=155ae068838' target=_blank style='color:#2F92EE;'>#疾病模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70688, encryptionId=155ae068838, topicName=疾病模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d72329409973, createdName=guguangxiang, createdTime=Fri Oct 28 12:30:05 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682742, encodeId=e6a21682e421c, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Sun May 07 17:30:05 CST 2023, time=2023-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890403, encodeId=6a02189040377, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jul 22 22:30:05 CST 2023, time=2023-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377803, encodeId=d18213e78033f, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404305, encodeId=c539140430514, content=<a href='/topic/show?id=6cfd14e93a0' target=_blank style='color:#2F92EE;'>#PSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14793, encryptionId=6cfd14e93a0, topicName=PSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=59b62453284, createdName=gjsgj, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448790, encodeId=8f9d1448e9096, content=<a href='/topic/show?id=c6dd1000849' target=_blank style='color:#2F92EE;'>#iPSCs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10008, encryptionId=c6dd1000849, topicName=iPSCs)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201103/27ddabe24d5c43739f1308f83d97be8c/4e3d31f92c9f4025bcf1d53b255ca4e5.jpg, createdBy=ffb85431490, createdName=caoliehu, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538833, encodeId=e8a9153883354, content=<a href='/topic/show?id=60de100065b' target=_blank style='color:#2F92EE;'>#iPSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10006, encryptionId=60de100065b, topicName=iPSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37d013060412, createdName=neurosurgeon, createdTime=Mon Aug 15 09:30:05 CST 2022, time=2022-08-15, status=1, ipAttribution=)]
    2022-08-15 neurosurgeon

相关资讯

Neurol Neuroimmunol Neuroinflamm:组织谷氨酰胺酶表达与多发性硬化的进展有关

PBMCs来源的TG2 mRNA水平与多发性硬化疾病进展的临床和放射学测量相关,因此有望作为多发性硬化特别是PP多发性硬化患者疾病进展的生物标志物。

Circulation Research:白细胞介素-6预测颈动脉斑块的严重程度、易损性和进展

循环IL-6水平可预测颈动脉斑块的严重程度、易损性和进展。以2.0pg/mL临界值可以帮助识别可以从抗IL-6药物进行脑卒中预防治疗中受益的个体。

盘点:近期肾病进展(十)

肾脏的生理功能主要是排泄代谢产物及调节水、电解质和酸碱平衡,分泌多种活性物质,维持机体内环境稳定,以保证机体的正常生理功能。肾炎是由免疫介导的、炎症介质(如补体、细胞因子、活性氧等)参与的,最后导致肾

盘点:近期前列腺疾病研究(十)

前列腺是男性生殖器附属腺中最大的实质性器官。由前列腺组织和肌组织构成。前列腺炎是指由多种复杂原因引起的,以尿道刺激症状和慢性盆腔疼痛为主要临床表现的前列腺疾病。前列腺炎是泌尿外科的常见病,在泌尿外科5

盘点:近期膀胱疾病进展(十)

膀胱是一个储尿器官。在哺乳类,它是由平滑肌组成的一个囊形结构,位于骨盆内,其后端开口与尿道相通。膀胱与尿道的交界处有括约肌,可以控制尿液的排出。膀胱为锥体形囊状肌性器官,位于小骨盆腔的前部。膀胱癌是指

Eur Urol:放疗复发的高风险前列腺癌的临床进展模式

超过50%的高风险前列腺癌男性患者 (HRPCa)(格里森4-5级疾病,或者临床T分期3-4级或前列腺特异性抗原(PSA)>20ng/ml)在长期随访中会出现生化复发(BCR)。放疗(RT)后的